Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
Table 1
Characteristics of the study population.
BiOSS group
DES group
No ISR
ISR
No ISR
ISR
(%)
(%)
(%)
(%)
Age (years)
66.6 ± 9.7
65.2 ± 12.6
66.5 ± 9.1
65.6 ± 9.5
Men (%)
141 (71.2%)
19 (79.2)
145 (70.4%)
14 (82.4)
HTN
158 (79.8%)
22 (91.7)
158 (76.7%)
13 (76.5)
Hypercholesterolemia
143 (72.2%)
17 (70.8)
136 (66%)
14 (82.4)
Diabetes type 2
82 (41.4%)
8 (33.3)
63 (30.6%)
9 (52.9)
Diabetes type 2 on insulin
19 (9.6%)
4 (16.7)
12 (5.8%)
4 (23.5)
Prior MI
85 (42.9%)
14 (58.3)
82 (39.8%)
8 (47.1)
Prior percutaneous coronary intervention
101 (51%)
11 (45.8)
109 (52.9%)
6 (35.3)
CABG
17 (8.6%)
4 (16.7)
19 (9.2%)
3 (17.6)
CKD
22 (11.1%)
1 (4.2)
16 (7.8%)
3 (17.6)
Smoking
44 (22.2%)
3 (12.5)
50 (24.3%)
7 (41.2)
Indications for revascularization
Stable CAD
167 (84.3%)
19 (79.2)
176 (85.4%)
10 (58.8)
NSTE-ACS
31 (15.7%)
5 (20.8)
30 (14.6%)
7 (41.2)
Medina 1.1.1; 1.0.1; 0.1.1
167 (84.3%)
11 (45.8)
176 (85.4%)
9 (52.9)
LM bifurcation
57 (28.8%)
5 (20.8)
51 (24.8%)
6 (35.3)
No ISR vs. ISR in BiOSS or DES groups. ISR between BiOSS and DESs groups. CAD: coronary artery disease, CKD: chronic kidney disease; CABG: coronary artery bypass graft; ISR: in-stent restenosis; HTN: arterial hypertension; LM: left main; MI: myocardial infarction; NSTE-ACS: nonST elevation acute coronary syndrome.
